Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Makoto Shiragami

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|December 4, 2018
[Problems with Advertisements for Health Foods]Makoto Shiragami
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|April 7, 2017
Greeting and General Statement by the OrganizerMakoto Shiragami
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|April 16, 2003
[Pharmacoeconomics]Makoto Shiragami
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|September 9, 2010
[Detection of adverse drug reactions with the use of a simple questionnaire]Hironori Tsuchiya, Makoto Shiragami
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|February 3, 2009
[Reasonable dispensing fee for patients]Rie Aoki, Makoto Shiragami
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|March 3, 2007
Objective evaluation of generic-specific drug informationHisashi Iijima, Toshimasa Koshimizu, Makoto Shiragami
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|September 6, 2005
[Evaluation of information for generic drugs based on importance and necessity]Hisashi Iijima, Miwako Kamei, Toshimasa Koshimizu, et al.
Journal of Pharmaceutical Policy and Practice|August 20, 2014
Contribution of antimicrobial stewardship programs to reduction of antimicrobial therapy costs in community hospital with 429 Beds --before-after comparative two-year trial in JapanTetsuya Fukuda, Hidemi Watanabe, Saeko Ido, et al.
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|October 9, 2010
Acceptable incremental cost effectiveness ratio for use of new drugs, cases in statin therapiesSusumu Nakao, Hiroyuki Kawabe, Hiroki Takuma, et al.
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|June 1, 2004
Objective evaluation of generic drug informationHisashi Iijima, Miwako Kamei, Toshimasa Koshimizu, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|December 4, 2018
[Problems with Advertisements for Health Foods]Makoto Shiragami
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|April 7, 2017
Greeting and General Statement by the OrganizerMakoto Shiragami
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|April 16, 2003
[Pharmacoeconomics]Makoto Shiragami
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|September 9, 2010
[Detection of adverse drug reactions with the use of a simple questionnaire]Hironori Tsuchiya, Makoto Shiragami
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|February 3, 2009
[Reasonable dispensing fee for patients]Rie Aoki, Makoto Shiragami
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|March 3, 2007
Objective evaluation of generic-specific drug informationHisashi Iijima, Toshimasa Koshimizu, Makoto Shiragami
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|September 6, 2005
[Evaluation of information for generic drugs based on importance and necessity]Hisashi Iijima, Miwako Kamei, Toshimasa Koshimizu, et al.
Journal of Pharmaceutical Policy and Practice|August 20, 2014
Contribution of antimicrobial stewardship programs to reduction of antimicrobial therapy costs in community hospital with 429 Beds --before-after comparative two-year trial in JapanTetsuya Fukuda, Hidemi Watanabe, Saeko Ido, et al.
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|October 9, 2010
Acceptable incremental cost effectiveness ratio for use of new drugs, cases in statin therapiesSusumu Nakao, Hiroyuki Kawabe, Hiroki Takuma, et al.
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|June 1, 2004
Objective evaluation of generic drug informationHisashi Iijima, Miwako Kamei, Toshimasa Koshimizu, et al.
Pageof 3